BACKGROUND: Dengue viruses (DENV-1-4) pose a transfusion-transmission risk. This study estimated the dengue RNA detection period in asymptomatic blood donors and relationships between donor viremia and dengue incidence during a large epidemic. METHODS: Donor samples from the 2012 dengue transmission season in Rio de Janeiro, Brazil, were tested for DENV RNA by a transcription-mediated amplification (TMA) assay, with DENV types and viral loads determined by polymerase chain reaction. Samples collected during the first and last weeks of enrollment were tested for DENV immunoglobulin (Ig) G and IgM to estimate incidence during the study period, which was analyzed relative to nucleic acid amplification technology (NAT) yield to estimate the duration of NAT-detectable viremia and compared with reported clinical dengue cases in Rio. RESULTS: Samples from 16 241 donations were tested; 87 (0.54%) were confirmed as DENV-4 RNA positive. Dengue IgM-positive/IgG-positive reactivity increased from 2.8% to 8.8%, indicating a 6.2% incidence (95% confidence interval [CI], 3.2%-9.1%) during the study period. Based on these data, we estimated a 9.1-day period (95% CI, 4.4-13.9 days) of RNA detectable with TMA. With 100 475 reported cases of clinical dengue, 1 RNA-positive donation was identified per 800 DENV cases. CONCLUSIONS: These parameters allow projections of dengue incidence from donor NAT yield data and vice versa, and suggest that viremic donations will be rare relative to clinical disease cases.
BACKGROUND:Dengue viruses (DENV-1-4) pose a transfusion-transmission risk. This study estimated the dengue RNA detection period in asymptomatic blood donors and relationships between donorviremia and dengue incidence during a large epidemic. METHODS:Donor samples from the 2012 dengue transmission season in Rio de Janeiro, Brazil, were tested for DENV RNA by a transcription-mediated amplification (TMA) assay, with DENV types and viral loads determined by polymerase chain reaction. Samples collected during the first and last weeks of enrollment were tested for DENV immunoglobulin (Ig) G and IgM to estimate incidence during the study period, which was analyzed relative to nucleic acid amplification technology (NAT) yield to estimate the duration of NAT-detectable viremia and compared with reported clinical dengue cases in Rio. RESULTS: Samples from 16 241 donations were tested; 87 (0.54%) were confirmed as DENV-4 RNA positive. Dengue IgM-positive/IgG-positive reactivity increased from 2.8% to 8.8%, indicating a 6.2% incidence (95% confidence interval [CI], 3.2%-9.1%) during the study period. Based on these data, we estimated a 9.1-day period (95% CI, 4.4-13.9 days) of RNA detectable with TMA. With 100 475 reported cases of clinical dengue, 1 RNA-positive donation was identified per 800 DENV cases. CONCLUSIONS: These parameters allow projections of dengue incidence from donor NAT yield data and vice versa, and suggest that viremic donations will be rare relative to clinical disease cases.
Authors: Maria da Glória Teixeira; Maria da Conceição Nascimento Costa; Maurício Lima Barreto; Eduardo Mota Journal: Cad Saude Publica Date: 2005-09-12 Impact factor: 1.632
Authors: Desiree Matos; Kay M Tomashek; Janice Perez-Padilla; Jorge Muñoz-Jordán; Elizabeth Hunsperger; Kalanthe Horiuchi; David Noyd; Colleen Winton; Gregory Foster; Marion Lanteri; Jeffrey M Linnen; Susan L Stramer Journal: Transfusion Date: 2015-09-07 Impact factor: 3.157
Authors: Vivien W M Chuang; T Y Wong; Y H Leung; Edmond S K Ma; Y L Law; Owen T Y Tsang; K M Chan; Iris H L Tsang; T L Que; Raymond W H Yung; S H Liu Journal: Hong Kong Med J Date: 2008-06 Impact factor: 2.227
Authors: Susan L Stramer; Jeffrey M Linnen; James M Carrick; Gregory A Foster; David E Krysztof; Shimian Zou; Roger Y Dodd; Lourdes M Tirado-Marrero; Elizabeth Hunsperger; Gilberto A Santiago; Jorge L Muñoz-Jordan; Kay M Tomashek Journal: Transfusion Date: 2012-02-17 Impact factor: 3.157
Authors: Michael P Busch; Steven H Kleinman; Leslie H Tobler; Hany T Kamel; Philip J Norris; Irina Walsh; Jose L Matud; Harry E Prince; Robert S Lanciotti; David J Wright; Jeffrey M Linnen; Sally Caglioti Journal: J Infect Dis Date: 2008-10-01 Impact factor: 5.226
Authors: Marcio Roberto Teixeira Nunes; Nuno Rodrigues Faria; Helena Baldez Vasconcelos; Daniele Barbosa de Almeida Medeiros; Clayton Pereira Silva de Lima; Valéria Lima Carvalho; Eliana Vieira Pinto da Silva; Jedson Ferreira Cardoso; Edivaldo Costa Sousa; Keley Nascimento Barbosa Nunes; Sueli Guerreiro Rodrigues; Ana Barroso Abecasis; Marc A Suchard; Philippe Lemey; Pedro Fernando da Costa Vasconcelos Journal: Emerg Infect Dis Date: 2012-11 Impact factor: 6.883
Authors: David W Brown; Michael J Griffiths; Raquel Medialdea-Carrera; Flavia Levy; Priscila Castanha; Patricia Carvalho de Sequeira; Patricia Brasil; Lia L Lewis-Ximenez; Lance Turtle; Tom Solomon; Ana Maria Bispo de Filippis Journal: J Clin Microbiol Date: 2021-09-22 Impact factor: 5.948
Authors: Ángel Giménez-Richarte; Mabel Ortiz de Salazar; Cristina Arbona; María P Giménez-Richarte; Miriam Collado; Pedro L Fernández; Francisco Quiles; Carlos Clavijo; Pascual Marco; Jose-Manuel Ramos-Rincon Journal: Blood Transfus Date: 2021-09-22 Impact factor: 5.752
Authors: Rafael Dos Santos Bezerra; Leonardo Scalon de Oliveira; Edson L Moretto; Eugênia M Amorim Ubiali; Roberta Maraninchi Silveira; Wilson A da Silva; Dimas Tadeu Covas; Simone Kashima; Svetoslav N Slavov Journal: Blood Transfus Date: 2020-07-22 Impact factor: 3.443